Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats

Stadler, Krisztian ; Jenei, Veronica LU ; Somogyi, Aniko and Jakus, Judit (2005) In Diabetes/Metabolism Research & Reviews 21(2). p.189-196
Abstract
BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was... (More)
BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was able to prevent hypertrophic alterations and reduce protein carbonylation in the cardiac tissue. CONCLUSIONS: Oxidative protein modification, together with cardiac hypertrophy and high generation of *NO and ONOO-, are important early events in the development of cardiovascular complications in diabetes. Aminoguanidine could prevent hypertrophy through inhibition of production of nonenzymatic glycation products rather than via inhibition of *NO production. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
aminoguanidine, insulin, nitric oxide, diabetes, cardiac hypertrophy, EPR spectroscopy
in
Diabetes/Metabolism Research & Reviews
volume
21
issue
2
pages
189 - 196
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:15386808
  • scopus:16344393699
  • pmid:15386808
ISSN
1520-7552
DOI
10.1002/dmrr.501
language
English
LU publication?
yes
id
99b035a6-4d8b-431f-8594-571284eff144 (old id 1133171)
date added to LUP
2016-04-01 12:06:25
date last changed
2022-01-26 22:51:55
@article{99b035a6-4d8b-431f-8594-571284eff144,
  abstract     = {{BACKGROUND: The study focused on investigating the effect of aminoguanidine on cardiovascular damages in diabetes and the possible mechanisms of its action. METHODS: Aminoguanidine (AMNG) was used to treat streptozotocin-induced diabetic rats, and the effects were compared to those obtained under insulin treatment. Blood metabolic parameters, *NO and ONOO- as well as protein carbonyl levels and cardiac hypertrophy were determined. RESULTS: Diabetic animals showed increased *NO levels and markedly increased ONOO- generation in the aorta, along with a significant hypertrophy and protein carbonylation in the cardiac tissue. Both AMNG and insulin treatment suppressed the levels of overproduced *NO or ONOO- in the vasculature, but only AMNG was able to prevent hypertrophic alterations and reduce protein carbonylation in the cardiac tissue. CONCLUSIONS: Oxidative protein modification, together with cardiac hypertrophy and high generation of *NO and ONOO-, are important early events in the development of cardiovascular complications in diabetes. Aminoguanidine could prevent hypertrophy through inhibition of production of nonenzymatic glycation products rather than via inhibition of *NO production.}},
  author       = {{Stadler, Krisztian and Jenei, Veronica and Somogyi, Aniko and Jakus, Judit}},
  issn         = {{1520-7552}},
  keywords     = {{aminoguanidine; insulin; nitric oxide; diabetes; cardiac hypertrophy; EPR spectroscopy}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{189--196}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Diabetes/Metabolism Research & Reviews}},
  title        = {{Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats}},
  url          = {{http://dx.doi.org/10.1002/dmrr.501}},
  doi          = {{10.1002/dmrr.501}},
  volume       = {{21}},
  year         = {{2005}},
}